These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35648149)

  • 41. Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.
    Suzuki Y; Oda A; Negami J; Toyama D; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Lipid Res; 2022 Mar; 63(3):100184. PubMed ID: 35181316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
    Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
    Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
    Wilson A; Tirona RG; Kim RB
    Inflamm Bowel Dis; 2017 May; 23(5):804-813. PubMed ID: 28301431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.
    Naito T; Kubono N; Ishida T; Deguchi S; Sugihara M; Itoh H; Kanayama N; Kawakami J
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):419-24. PubMed ID: 26654672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.
    Wollmann BM; Syversen SW; Lie E; Gjestad C; Mehus LL; Olsen IC; Molden E
    Clin Transl Sci; 2017 Jan; 10(1):42-49. PubMed ID: 27991741
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.
    Huang MQ; Lin W; Wang W; Zhang W; Lin ZJ; Weng N
    Biomed Chromatogr; 2014 Jun; 28(6):794-801. PubMed ID: 24861746
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
    Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
    Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
    He P; Court MH; Greenblatt DJ; Von Moltke LL
    Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
    Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
    Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro.
    Deb S; Chin MY; Adomat H; Guns ES
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():50-8. PubMed ID: 24269662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
    Jamwal R; de la Monte SM; Ogasawara K; Adusumalli S; Barlock BB; Akhlaghi F
    Mol Pharm; 2018 Jul; 15(7):2621-2632. PubMed ID: 29792708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
    Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
    J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Mansell SE; Kim RB; Tirona RG; Beaton MD
    Drug Metab Dispos; 2015 Oct; 43(10):1484-90. PubMed ID: 26231377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
    Dong JQ; Gosset JR; Fahmi OA; Lin Z; Chabot JR; Terra SG; Le V; Chidsey K; Nouri P; Kim A; Buckbinder L; Kalgutkar AS
    Drug Metab Dispos; 2017 May; 45(5):501-511. PubMed ID: 28254951
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
    Phimmasone S; Kharasch ED
    Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
    Tomalik-Scharte D; Lütjohann D; Doroshyenko O; Frank D; Jetter A; Fuhr U
    Clin Pharmacol Ther; 2009 Aug; 86(2):147-53. PubMed ID: 19458613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4.
    Sevrioukova IF; Poulos TL
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):486-491. PubMed ID: 28031486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.